{"id":5628,"date":"2008-07-05T14:48:00","date_gmt":"2008-07-05T14:48:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=5628"},"modified":"2021-07-09T11:17:31","modified_gmt":"2021-07-09T11:17:31","slug":"selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/","title":{"rendered":"Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Maiden+L&amp;cauthor_id=18521900\">Laurence Maiden<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18521900\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Takeuchi+K&amp;cauthor_id=18521900\">Ken Takeuchi<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Baur+R&amp;cauthor_id=18521900\">Rosie Baur<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Bjarnason+I&amp;cauthor_id=18521900\">Ingi Bjarnason<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=O%27Donohue+J&amp;cauthor_id=18521900\">John O&rsquo;Donohue<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Forgacs+I&amp;cauthor_id=18521900\">Ian Forgacs<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Chung-Faye+G&amp;cauthor_id=18521900\">Guy Chung-Faye<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Sanderson+J&amp;cauthor_id=18521900\">Jeremy Sanderson<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Bjarnason+I&amp;cauthor_id=18521900\">Ingvar Bjarnason<\/a>, Inflamm Bowel Dis. 2008 Oct;14(10):1413-8.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>This study represents a new approach to the treatment of IBD by targeting a group of asymptomatic patients for treatment who are at significant risk of relapse based on high fecal calprotectin concentrations. Selective leukocytapheresis significantly reduced the number of, and increased the time to, clinical relapse in these patients without serious side effects.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18521900\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/18521900\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Laurence Maiden&nbsp;1,&nbsp;Ken Takeuchi,&nbsp;Rosie Baur,&nbsp;Ingi Bjarnason,&nbsp;John O&rsquo;Donohue,&nbsp;Ian Forgacs,&nbsp;Guy Chung-Faye,&nbsp;Jeremy Sanderson,&nbsp;Ingvar Bjarnason, Inflamm Bowel Dis. 2008 Oct;14(10):1413-8. This study represents a new approach to the treatment of IBD by targeting a group of asymptomatic patients for treatment who are at significant risk of relapse based on high fecal calprotectin concentrations. Selective leukocytapheresis significantly reduced the number of, [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[159,314,306],"class_list":["post-5628","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-crohns-disease","scientific_tags-digestive","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Laurence Maiden&nbsp;1,&nbsp;Ken Takeuchi,&nbsp;Rosie Baur,&nbsp;Ingi Bjarnason,&nbsp;John O&rsquo;Donohue,&nbsp;Ian Forgacs,&nbsp;Guy Chung-Faye,&nbsp;Jeremy Sanderson,&nbsp;Ingvar Bjarnason, Inflamm Bowel Dis. 2008 Oct;14(10):1413-8. This study represents a new approach to the treatment of IBD by targeting a group of asymptomatic patients for treatment who are at significant risk of relapse based on high fecal calprotectin concentrations. Selective leukocytapheresis significantly reduced the number of, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-09T11:17:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/\",\"name\":\"Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2008-07-05T14:48:00+00:00\",\"dateModified\":\"2021-07-09T11:17:31+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/","og_locale":"fr_FR","og_type":"article","og_title":"Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse - Adacyte","og_description":"Laurence Maiden&nbsp;1,&nbsp;Ken Takeuchi,&nbsp;Rosie Baur,&nbsp;Ingi Bjarnason,&nbsp;John O&rsquo;Donohue,&nbsp;Ian Forgacs,&nbsp;Guy Chung-Faye,&nbsp;Jeremy Sanderson,&nbsp;Ingvar Bjarnason, Inflamm Bowel Dis. 2008 Oct;14(10):1413-8. This study represents a new approach to the treatment of IBD by targeting a group of asymptomatic patients for treatment who are at significant risk of relapse based on high fecal calprotectin concentrations. Selective leukocytapheresis significantly reduced the number of, [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/","og_site_name":"Adacyte","article_modified_time":"2021-07-09T11:17:31+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/","name":"Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2008-07-05T14:48:00+00:00","dateModified":"2021-07-09T11:17:31+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-white-cell-apheresis-reduces-relapse-rates-in-patients-with-ibd-at-significant-risk-of-clinical-relapse\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/5628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=5628"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=5628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}